CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1228)

INSIDE INFORMATION ANNOUNCEMENT
邁芮倍®/LIVMARLI® (MARALIXIBAT ORAL SOLUTION, CAN108) OBTAINED MARKETING APPROVAL IN CHINA

This announcement is made by CANbridge Pharmaceuticals Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Director(s)**") of the Company hereby informs the shareholders and potential investors of the Company that 邁芮倍®/LIVMARLI® (Maralixibat Oral Solution, CAN108) has been granted marketing approval by the National Medical Products Administration (the "**NMPA**") of the People's Republic of China ("**China**"), for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older. The Company acquired the exclusive right for the development, commercialization and manufacturing, under certain conditions, of LIVMARLI® in Greater China from Mirum Pharmaceuticals, Inc. for three rare liver disease indications, including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA), as well as other select indications. LIVMARLI® is currently being investigated in an ongoing Global Phase 2 study (EMBARK) for biliary atresia.

INFORMATION ABOUT ALAGILLE SYNDROME

Alagille syndrome (ALGS) is an autosomal dominant multisystem disorder which can lead to end-stage liver disease and death. It has been registered in National Rare Diseases Registry System of China (NRDRS). This disease is characterized by dysplasia of bile ducts and involvement of extrahepatic organs, such as the kidneys and eyes, as well as bones and the cardiovascular system.

INFORMATION ABOUT LIVMARLI®

LIVMARLI® (Maralixibat Oral Solution, CAN108) is a minimally absorbed ileal bile acid transporter (IBAT) inhibitor that blocks the enterohepatic circulation of bile acids, reduces bile acid levels in the liver and serum, reduces the resultant liver injury and relieves pruritus (extreme itching). LIVMARLI® is the first, and only medication approved in China, the US and EU to treat cholestatic pruritus associated with Alagille syndrome (ALGS).

In addition to ALGS, LIVMARLI® is under clinical development by the Company for the treatment of other cholestatic liver diseases, including PFIC and BA, and has been granted Orphan Drug designation by the Food and Drug Administration (FDA) of the United States. The Company acquired the exclusive right to develop and commercialize LIVMARLI® in Greater China from Mirum Pharmaceuticals, Inc. for ALGS, PFIC and BA, as well as other select indications.

INFORMATION ABOUT THE COMPANY

The Company is principally engaged in the research, development and commercialization of biotech therapies targeting rare diseases in large underserved global markets. The Company has a differentiated drug portfolio, with 4 approved drugs and a pipeline of 10 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that LIVMARLI® (Maralixibat Oral Solution, CAN108) will ultimately be successfully commercialized by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, June 1, 2023

As at the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Dr. Kan Chen, Dr. Derek Paul Di Rocco and Mr. Edward Hu as non-executive Directors; and Mr. James Arthur Geraghty, Dr. Richard James Gregory, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.